Halozyme (HALO) Loses 9% on Weak Earnings
In an updated report, Halozyme Therapeutics Inc.
Halozyme Therapeutics Inc. (HALO)
Market is closed
Hedge Fund Popularity
Hedge Fund Holdings
Filing Period:
Last updated on based on SEC 13F filings Last update:
| No. | Hedge Fund | Shares | Value | Activity | % Port |
|---|---|---|---|---|---|
| 1. | Arrowstreet Capital Peter Rathjens, Bruce Clarke And John Campbell | 3,222,507 | $216,874,721 | -3% | 0.13% |
| 2. | D E Shaw D. E. Shaw | 1,649,466 | $111,009,062 | -38% | 0.06% |
| 3. | Millennium Management Israel Englander | 1,463,948 | $98,523,700 | +20% | 0.04% |
| 4. | AQR Capital Management Cliff Asness | 1,158,359 | $77,957,548 | +20% | 0.04% |
| 5. | 40,851,000 | $54,243,628 | +42% | 0.06% |
Insider Trading: Purchases See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $14.24 | 17,543 | $249,780.74 | 277,553 | 2020-03-19 | Filing | |
| $14.25 | 17,543 | $249,982.49 | 260,010 | 2020-03-19 | Filing | |
| $14.19 | 17,543 | $248,933.42 | 242,467 | 2020-03-19 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing | |
| $17.24 | 10,000 | $172,384.00 | 10,000 | 2015-08-20 | Filing |
Insider Trading: Sales See All
| Insider | Price | Amount | Total Value | Remaining Holdings | Date | Form 4 |
|---|---|---|---|---|---|---|
| $78.94 | 4,624 | $365,000.06 | 708,719 | 2026-02-05 | Filing | |
| $78.38 | 5,376 | $421,365.50 | 713,343 | 2026-02-05 | Filing | |
| $77.54 | 10,100 | $783,154.00 | 708,719 | 2026-02-04 | Filing | |
| $76.94 | 9,900 | $761,666.40 | 718,819 | 2026-02-04 | Filing | |
| $76.73 | 7,790 | $597,757.86 | 708,719 | 2026-02-03 | Filing |
Institutional Investors' Holdings
Filing Period:
| No. | Name | Shares | Value | % Port |
|---|---|---|---|---|
| 1. | 13,153,857 | $885,254,609 | 0.01% | |
| 2. | 11,566,896 | $778,452,101 | 0.01% | |
| 3. | 5,121,672 | $344,688,526 | 0.01% | |
| 4. | 3,648,063 | $245,514,640 | 0.04% | |
| 5. | 2,733,832 | $183,986,863 | 0.01% |
News See All
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript
Halozyme Therapeutics, Inc. (NASDAQ:HALO) Q4 2025 Earnings Call Transcript February 17, 2026Halozyme Therapeutics, Inc. misses on earnings expectations.
H.C. Wainwright Sees Strength in Halozyme Therapeutics' ENHANZE Platform, Reiterates Buy Rating
On January 9, H.C. Wainwright reiterated a Buy rating on Halozyme Therapeutics, Inc. (NASDAQ:HALO), maintaining the price target at $90. Mitchell Kapoor from H.C.
11 Best Stocks to Buy for Investment
Following growing uncertainty in global markets amid heightened geopolitical tensions, the U.S. market rebounded this week.
TD Cowen Notes Shifting Positive Sentiment for Halozyme (HALO) Ahead of Q4 Earnings, 2026 Guidance
Halozyme Therapeutics Inc. (NASDAQ:HALO) is one of the best mid-cap growth stocks to buy right now. On January 8, TD Cowen raised its price target on Halozyme to $90 from $79 and kept a Buy rating.
14 Best Mid-Cap Growth Stocks to Buy Right Now
On January 8, Nancy Prial, Co-CEO & Senior Portfolio Manager at Essex Investment Management, appeared on CNBC and suggested she sees significant upside in 2026 for undiscovered small- and midcap firms...
Halozyme (HALO) Boosted by ENHANZE Launches and Analyst Upgrade
Halozyme Therapeutics, Inc. (NASDAQ:HALO) ranks among the 10 best new stocks to buy in Ray Dalio’s portfolio. On January 8, TD Cowen boosted Halozyme Therapeutics, Inc.
Ray Dalio Stock Portfolio: 10 New Stock Picks
Ray Dalio devoted 2025 advised caution regarding the stock market, and he remains worried as the US economy moves forward in 2026.
Here's What Analysts Think About Halozyme Therapeutics (HALO)
Halozyme Therapeutics, Inc. (NASDAQ:HALO) is one of the best affordable stocks with good earnings growth for 2026. Halozyme Therapeutics, Inc.
7 Affordable Stocks With Good Earnings Growth for 2026
On December 29, Jeremy Siegel, professor emeritus of finance at the University of Pennsylvania and chief economist at WisdomTree, appeared on CNBC's “Squawk Box” to talk about the outlook for 2026...
Hedge Fund Resource Center